Jim Cramer on Crinetics: “That’s a Better Spec Than Aquestive”

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the stocks Jim Cramer recently looked at. Answering a caller’s query about the stock during the lightning round, Cramer said:

Yes, I think that Goldman Sachs just put out a Buy recommendation on it, and I think that’s a, see, that’s a better spec than Aquestive. That’s the whole point. See, you want something, at least a major firm has come out and… vetted it. They have the money. I say go with CRNX, but it’s a $55 stock. See, it’s not a little dollar stock, and people don’t want to buy $4 to $6 stocks. Don’t. Think about whether the company’s good, not whether the price is right.

Pixabay/Public Domain

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) creates oral drugs for rare hormonal diseases and tumors, with its lead candidate, Paltusotine, currently in Phase 3 trials for acromegaly and carcinoid syndrome. Moreover, its portfolio includes treatments for conditions like Cushing’s disease and obesity.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.